ERBB2 and gastric cancer: Finally, our experimental data suggest that targeting the HOTAIR/HER2 interaction may represent a novel therapeutic application, thus contributing to better knowledge of the efficacy and tolerance of trastuzumab-based therapy in HER2-positive gastric cancer patients.